7 news items
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FGEN
3 Jun 24
expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors. For more information
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FGEN
3 Jun 24
the development of an associated CD46-targeted PET biomarker. In addition, FibroGen has expanded its research and development portfolio to include two
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN
23 May 24
of an associated CD46-targeted PET biomarker. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology
FibroGen Reports First Quarter 2024 Financial Results
FGEN
6 May 24
PET biomarker. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates
FibroGen to Report First Quarter 2024 Financial Results
FGEN
29 Apr 24
biomarker. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment
defboja 61rvd7bw7vgmkgn1
FGEN
24 Apr 24
biomarker. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment
10obfcsfdth1yme4h2jdyy7bc8xez4od bvax
FGEN
2 Apr 24
. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors
- Prev
- 1
- Next